

A randomised, placebo-control phase III study to assess the safety and efficacy of the MPT64 patch test in the diagnosis of active tuberculosis (TB)

Submission date 13/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 11/11/2005	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 12/01/2021	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr David Moore

Contact details

Universidad Peruana Cayetano Heredia
Honorio Delgado 430
San Martin de Porres
Lima
Peru
Lima 31
+511 382 3398
davidajmoore@msn.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

SEQPTAT005

Study information

Scientific Title

A randomised, placebo-control phase III study to assess the safety and efficacy of the MPT64 patch test in the diagnosis of active tuberculosis (TB)

Study objectives

Cutaneous reaction to transdermal delivery of the Mycobacterium tuberculosis (MTB) specific protein MPT64 by means of a patch test will accurately identify individuals with active TB from amongst TB suspects.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Diagnostic

Participant information sheet

Health condition(s) or problem(s) studied

Active pulmonary tuberculosis.

Interventions

1. Diagnostic phase: application of a transdermal patch to each forearm, one containing placebo and the other MPT64 (study staff and patients blinded to allocation) with removal and reading of result at days 4 and 6. All patients receive full work-up for active pulmonary TB including clinical evaluation, two sputum cultures (each by two methods), chest radiograph and (on day 4) purified protein derivative (PPD) skin testing.
2. Follow-up phase: all participants are followed up at 3 months to verify correct baseline assignment as TB or non-TB; at months 9, 12, 15 and 18 all participants are investigated fully once more for TB (as above) and repeat patch testing is performed. In a subgroup of 30 consenting participants with positive reactions, skin punch biopsies are performed.

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

MTB specific protein MPT64

Primary outcome measure

The objective is to assess the sensitivity and specificity of the MPT64 patch test in the diagnosis of pulmonary TB - the outcome of interest is therefore the concordance of patch test results with the results of the conventional gold-standard investigations performed concurrently.

Secondary outcome measures

1. To assess the above performance characteristics in patient subgroups including those with smear-positive disease and smear-negative disease
2. To determine the effect (if any) of age, HIV status, PPD response upon patch test performance
3. To determine the response over time of both initial reactors and non-reactors and TB and non-TB patients
4. To characterize the histological response in patch test reactors

Overall study start date

20/02/2005

Completion date

01/05/2007

Eligibility**Key inclusion criteria**

TB suspects undergoing investigation at selected health centres for pulmonary TB within the National TB Control Programme of Peru.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

624

Total final enrolment

512

Key exclusion criteria

1. Age less than 18 or greater than 65
2. Inability or unwillingness to provide written informed consent
3. Participation in a clinical trial of another investigational product within the preceding 6 months
4. Refusal to undergo voluntary counselling and testing for human immunodeficiency virus (HIV) infection

Date of first enrolment

20/02/2005

Date of final enrolment

01/05/2007

Locations**Countries of recruitment**

Peru

Study participating centre

Universidad Peruana Cayetano Heredia

Lima

Peru

Lima 31

Sponsor information**Organisation**

Sequella Inc (USA)

Sponsor details

9610 Medical Center Drive

Suite 200

Rockville

United States of America

MD 20850

+1 301 762 7776

katherinesacksteder@sequella.com

Sponsor type

Industry

Website

<http://www.sequella.com>

ROR

Funder(s)

Funder type

Industry

Funder Name

Entirely funded by Sequella Inc.

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2018	12/01/2021	Yes	No